Litcius/Paper detail

Safety and efficacy of repeat ivermectin mass drug administrations for malaria control (RIMDAMAL II): a phase 3, double-blind, placebo-controlled, cluster-randomised, parallel-group trial

Anyirékun Fabrice Somé, Anthony Somé, Emmanuel Sougué, Cheick Oumar W. Ouédraogo, Ollo Da, S. Rodrigue Dah, Frédéric Nikièma, Tereza Magalhães, Lyndsey Gray, Will Finical, Greg Pugh, Paula Lado, Jenna C. Randall, Timothy A. Burton, Molly E. Ring, A Leon, McKenzie Colt, Fangyong Li, Kaicheng Wang, Martina Wade, Audun Lier, Kacey Richards, Hannah Sproch, Elizabeth Zhang, Julia Ellman, Ijeamaka Achebe, Conner Jackson, Mengli Xiao, Emma J. Wu, Teun Bousema, Hannah Slater, Brian D. Foy, Sunil Parikh, Roch K. Dabiré

2025The Lancet Infectious Diseases23 citationsDOIOpen Access PDF

Topics & Concepts

Double blindPlaceboMedicineMalariaCluster (spacecraft)Cluster randomised controlled trialDrugRandomized controlled trialInternal medicinePharmacologyAlternative medicineImmunologyComputer scienceProgramming languagePathologyMalaria Research and ControlParasitic Diseases Research and TreatmentParasites and Host Interactions
Safety and efficacy of repeat ivermectin mass drug administrations for malaria control (RIMDAMAL II): a phase 3, double-blind, placebo-controlled, cluster-randomised, parallel-group trial | Litcius